Friday, 16 October 2026European Markets

CHRISTIAN DIOR Stock 11.51% Up Before The Weekend

Loading stream...

(vianews) - the market ended the session with christian dior (cdi.pa) jumping 11.51% to €731.50 on friday, after two sequential sessions in a row of gains. cac 40 jumped 2.28% to €7,634.14, after two consecutive sessions in a row of gains, on what was an all-around positive trend trading session today.

christian dior's last close was €656.00, 24.77% below its 52-week high of €872.00.

about christian dior

christian dior se, through its subsidiaries, engages in the production, distribution, and retail of fashion and leather goods, wines and spirits, perfumes and cosmetics, and watches and jewelry worldwide. the company offers its fashion and leather goods under the louis vuitton, fendi, celine, loewe, givenchy, kenzo, berluti, pucci, loro piana, rimowa, and off-white brand names; and wines and spirits under the hennessy, moët & chandon, dom pérignon, veuve clicquot, krug, château d'yquem, belvedere, glenmorangie, newton vineyards, bodega numanthia, château d'esclans, armand de brignac, and joseph phelps brands. it also provides perfumes and cosmetics under the parfums christian dior, guerlain, parfums givenchy, make up for ever, benefit cosmetics, fresh, acqua di parma, kvd vegan beauty, fenty, ole henriksen, maison francis kurkdjian, and officine universelle buly 1803 brand names; and watches and jewelry under the tiffany, bulgari, tag heuer, zenith, hublot, chaumet, fred, and repossi brands. in addition, the company operates retail stores under the dfs galleria, sephora, and le bon marché names; publishes le parisien-aujourd'hui en france, a daily newspaper; builds yachts; and operates hotel and the cova pastry shop brand. further, it is involved in real estate activities. the company sells its products through store network, including e-commerce websites; and agents and distributors. the company was incorporated in 1946 and is headquartered in paris, france. christian dior se (enxtpa:cdi) operates as a subsidiary of financière agache société anonyme.

earnings per share

as for profitability, christian dior has a trailing twelve months eps of €36.74.

pe ratio

christian dior has a trailing twelve months price to earnings ratio of 19.91. meaning, the purchaser of the share is investing €19.91 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 31.06%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, christian dior's stock is considered to be oversold (<=20).

volatility

christian dior's last week, last month's, and last quarter's current intraday variation average was a positive 0.68%, a negative 0.36%, and a positive 1.03%.

christian dior's highest amplitude of average volatility was 0.80% (last week), 0.96% (last month), and 1.03% (last quarter).

dividend yield

as claimed by morningstar, inc., the next dividend payment is on dec 4, 2023, the estimated forward annual dividend rate is 12.5 and the estimated forward annual dividend yield is 1.96%.

more news about christian dior (cdi.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com